Immunomodulatory News and Research

RSS

New approach to COVID-19 immune profiling using blood-based machine learning

A new study discusses the application of a novel deconvolution model AImmune to predict moderate and severe cases of COVID-19.

5 Dec 2021

Teriflunomide tempers lesion growth in pediatric patients with multiple sclerosis

There are few treatment options for children with multiple sclerosis-;a condition in which the immune system attacks the protective covering of nerves in the brain and spinal cord-;and most therapies for the disease have not been tested in children.

30 Nov 2021

Oral Hsp90 inhibitor SNX-5422 interferes with replication machinery of SARS-CoV-2

A new study evaluates the efficacy of SNX-5422 as a post-exposure prophylactic treatment.

23 Nov 2021

Short-term severe calorie restriction safe, feasible, and well tolerated by cancer patients

A diet involving short-term, severe calorie restriction was safe, feasible, and resulted in a decrease of blood glucose and growth factor concentration, reduction in peripheral blood immunosuppressive cells, and enhanced intratumor T-cell infiltration in cancer patients receiving standard-of-care therapy, according to the results of a clinical trial.

18 Nov 2021

Study reveals complex interplay between diet, gut microbiota, and immune function

The cliché "you are what you eat" has been used for hundreds of years to illustrate the link between diet and health. Now, an international team of researchers has found the molecular proof of this concept, demonstrating how diet ultimately affects immunity through the gut microbiome.

17 Nov 2021

Macrophages located in the cardiac tissue protect the failing heart

According to the Centers for Disease Control and Prevention, heart failure affects more than 6 million Americans and is the main cause of death for one in eight patients.

12 Nov 2021

HSS study provides insight into real-world medication use for treatment of psoriatic arthritis

Despite clear directives outlined in the updated guidelines published by the American College of Rheumatology/National Psoriasis Foundation (ACR/NPF) in 2018, there is limited data regarding medication use in real-world clinical practice and patient medication preferences for the treatment of psoriatic arthritis (PsA).

9 Nov 2021

Hemin as a potential therapy for COVID-19

The current study explores the antiviral activity of HO-1 induced by hemin against SARS-CoV-2 and attempts to describe the mechanism of its anti-viral action.

8 Nov 2021

Anti-inflammatory diets in COVID-19

A recent review of research published in the journal Diseases has shown that anti-inflammatory diets can be useful in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or reducing the severity of coronavirus disease 2019 (COVID-19).

3 Nov 2021

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

Israeli researchers evaluate the antibody response in ICPs to assess antibody-mediated immunity following vaccination with the Pfizer-BioNTech vaccine.

26 Oct 2021

Can targeting autophagy become a new approach to COVID-19 treatment?

In a recent review, the author discusses autophagy as a contributing mechanism of selected drugs that are currently being evaluated to treat COVID‐19.

25 Oct 2021

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin’s lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines.

25 Oct 2021

Factors contributing to a weak antibody response to the Pfizer COVID-19 vaccine

A new study discusses risk factors for the failure of seroconversion following full vaccination with the COVID-19 Pfizer vaccine.

18 Oct 2021

Severe COVID-19 pneumonia patients with high ferritin show better outcomes after steroid treatment

During the entire pandemic, physicians treating patients with severe Covid-19 pneumonia continuously looked for hints and signs on what may enable patients to have better outcomes.

15 Oct 2021

Impact of BRCA1 mRNA expression on survival of patients breast and colorectal cancer

Oncotarget published "Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients" which reported that LMNB2 is a chromatin remodeling protein that also plays a role in eukaryotic cell proliferation by organizing the nuclear membrane during mitosis.

13 Oct 2021

Key lessons from COVID-19 pandemic for scientific and clinical communities

In a paper published in the journal Cell, researchers have investigated and criticized clinical care management and drug administration within the pandemic.

4 Oct 2021

Effect of biologic therapy on COVID-19 in children suffering from rheumatic diseases

A new study aimed to determine the course of SARS-CoV-2 infection in children suffering from rheumatic disease and were receiving bDMARD treatment.

29 Sep 2021

Study reports on ex vivo drug delivery system for delivering MSCs to kidney disease patients

Scientists are reporting promising results in the early stages of a clinical trial designed to gauge the feasibility of a new type of treatment for people with acute kidney disease.

28 Sep 2021

Differences in blood gene expression among patients with varying COVID-19 severity

A new study published on the medRxiv* pre-print server and currently undergoing peer-review aims to answer this question through whole blood transcriptomics of individuals with varying degrees of COVID-19 severity. Transcriptomics, done by RNA sequencing, gives insights into the genes expressed in a cell at a given time point. It gives an analysis of all RNA molecules within a cell, in this case, whole blood.

23 Sep 2021

Thousands of vulnerable hospital patients set to benefit from new COVID-19 treatment

Thousands of vulnerable NHS patients in hospital due to COVID-19 are set to benefit from a ground-breaking new antibody treatment, the government has announced today (17 September 2021).

18 Sep 2021